title: Ethinylestradiol/Chlormadinone acetate for use in dermatological disorders.
abstract: The diagnosis and management of four cases of dermatological disorders, most of which are related to the endocrine disorder of androgen excess, are presented. Combined oral contraceptives (COCs) may be useful when well-tolerated hormonal therapy and/or when contraception is required. A female patient with androgenetic alopecia or female pattern balding, without underlying hyperandrogenism, was treated with ethinylestradiol/chlormadinone acetate (EE/CMA) 0.03 mg/2 mg for 6 months and experienced stabilization of hair loss (case report 1). A patient who had previously received a COC for an irregular menstrual pattern but again experienced irregular menses and also acne after stopping treatment was diagnosed with acne associated with polycystic ovary syndrome (PCOS) [case report 2]. After 6 month's treatment with EE/CMA 0.03 mg/2 mg, this patient had fewer acne lesions and became eumenorrheic. A third patient who had excess hair since childhood was diagnosed with idiopathic hirsutism (no underlying gynecological or endocrinological disorder was found) and was treated with EE/CMA 0.03 mg/2 mg (case report 3). Less hair growth was reported after 6 months' treatment. Case report 4 describes a patient who presented with oligomenorrhea and acne. She was diagnosed with PCOS with acne, seborrhea and mild hirsutism. Treatment with EE/CMA 0.03 mg/2 mg for 6 months resulted in improvements in her facial acne, seborrhea and hirsutism; she also became eumenorrheic. These four cases illustrate that EE/CMA may be a useful and well tolerated treatment option in the management of patients with dermatological disorders with or without hyperandrogenization.
authors: Deparment of Dermatology, Hospital Municipal of Badalona, Badalona, Barcelona, Spain.
authors: Mercedes
authors: M
authors: Gómez Vázquez
authors: Ramón
authors: R
authors: Navarra Amayuelas
authors: Marta
authors: M
authors: Lamarca
authors: Laura
authors: L
authors: Baquedano
authors: Sebastián
authors: S
authors: Romero Ruiz
authors: Eduardo
authors: E
authors: Vilar-Checa
authors: Maria D
authors: MD
authors: Iniesta
mesh_terms: D000328:Adult; D000728:Androgens / Q000378:metabolism*; D002715:Chlormadinone Acetate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D012871:Skin Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000728:Androgens; D003277:Contraceptives, Oral, Combined; C488302:ethinylestradiol-chlormadinone acetate; D002715:Chlormadinone Acetate; D004997:Ethinyl Estradiol